Drug Profile
DN3 27 1
Alternative Names: DN 3271Latest Information Update: 17 Jun 2001
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pneumocystis pneumonia
Most Recent Events
- 17 Jun 2001 No-Development-Reported for Pneumocystis pneumonia in USA (Unknown route)
- 20 Jan 1998 New profile
- 20 Jan 1998 Preclinical development for Pneumocystis pneumonia in USA (Unknown route)